September 30, 2022
2 min watch
Save
VIDEO: Visus acquires assets from ViewPoint Therapeutics
CHICAGO — In this video from Eyecelerator@AAO, Visus Therapeutics CEO Ben Bergo discusses the company’s acquisition of ViewPoint’s patents and how this will help it further develop treatment options for presbyopia and cataracts.
“By this acquisition, we now have a library of compounds to again develop an aggregation inhibitor to address this cataract that can develop, but also presbyopia,” Bergo said.
Published by:
Sources/Disclosures
Collapse
Source:
Bergo B. Visus Therapeutics. Presented at: Eyecelerator@AAO; Sept. 29, 2022; Chicago.
Disclosures:
Bergo reports being the CEO of Visus Therapeutics.
Read more about